EDIC (EPIDEMIOLOGY OF DIABETES INTERVENTIONS & COMPLICATIONS)

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 该方案主要是1型糖尿病及其并发症的流行病学研究，特别强调大血管疾病。 EDIC被设计为糖尿病控制和并发症试验（DCCT）参与者的长期随访。 DCCT于1994年完成，是一项众所周知的前瞻性随机试验，共有1，441名受试者随机接受强化血糖控制与常规血糖控制。 结果提供了令人信服的证据，证明血糖控制有利于预防微血管和神经系统并发症。 EDIC现在提供了一个对这一大组受试者进行持续前瞻性随访的机会，从而有望获得关于糖尿病并发症的发生、发病机制、风险因素和治疗的新数据。 EDIC还利用了基于DCCT中研究人群既往参与情况的既往意向治疗分析。 此外，EDIC促进了1型糖尿病大血管疾病的研究，这是DCCT在相对年轻的受试者（入组DCCT时13-39岁）参与5-9年期间无法充分解决的问题。 EDIC还纳入了涉及参与者家庭成员的遗传成分，以更多地了解基因对1型糖尿病长期并发症的发展和进展的贡献。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This protocol is primarily an epidemiological study of type 1 diabetes and its complications with particular emphasis on macrovascular disease. The EDIC is designed as a long-term follow-up of participants in the Diabetes Control and Complications Trial (DCCT). The DCCT, which was completed in 1994, was a well known prospective randomized trial of 1,441 subjects randomized to intense versus conventional glycemic control. The results provided compelling evidence of the benefit of glycemic control towards preventing microvascular and neurological complications. The EDIC now offers an opportunity for continued prospective follow-up of this large group of subjects, thus promising new data on the occurrence, pathogenesis, risk factors and treatments of diabetic complications. The EDIC also takes advantage of prior intention-to-treat analysis based on previous involvement of the study population in the DCCT. In addition, the EDIC facilitates the study of macrovascular disease in type 1 diabetes, an issue that the DCCT could not adequately address over the 5-9 year participation of the relatively young subjects (13-39 years old at enrollment in the DCCT). The EDIC also incorporates a genetic component involving family members of participants in order to learn more about the contribution of genes to the development and progression of the long-term complications of type 1 diabetes.